Payment overview · 2025
General Payments
$254.78
12 reported records · 7 companies
Healthcare provider profile · identity verified
Leonard Charles Glaser, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NAPLES, FL · NPI 1194752089
Verified facts
What the public records show
CMS Open Payments records show Leonard Charles Glaser, MD received $254.78 in general payments during 2025 across 12 reported records.
Philips North America LLC accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $52.06 | 20.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.73 | 19.9% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $38.95 | 15.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.29 | 14.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.80 | 13.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.74 | 9.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.21 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.78 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Diagnostic ECG Service Normalized: diagnostic ecg service |
Device | Philips North America LLC | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $38.95 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 920 | 276 |
| Amlodipine Besylate | Amlodipine Besylate | 695 | 213 |
| Losartan Potassium | Losartan Potassium | 657 | 209 |
| Lisinopril | Lisinopril | 454 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 102 |
| Metformin Hcl | Metformin Hcl | 283 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 83 |
| Omeprazole | Omeprazole | 249 | 81 |
| Sertraline Hcl | Sertraline Hcl | 209 | 55 |
| Trazodone Hcl | Trazodone Hcl | 198 | 61 |
| Alprazolam | Alprazolam | 195 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 60 |
| Simvastatin | Simvastatin | 174 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 64 |
| Alendronate Sodium | Alendronate Sodium | 164 | 53 |
| Allopurinol | Allopurinol | 152 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 41 |
| Gabapentin | Gabapentin | 124 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 28 |
| Eliquis | Apixaban | 101 | 27 |
| Glimepiride | Glimepiride | 101 | 29 |
| Ozempic | Semaglutide | 93 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 38 |
| Furosemide | Furosemide | 90 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 27 |
| Carvedilol | Carvedilol | 83 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 26 |
| Meloxicam | Meloxicam | 81 | 24 |
| Montelukast Sodium | Montelukast Sodium | 81 | 26 |
| Prednisone | Prednisone | 79 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 28 |
| Ezetimibe | Ezetimibe | 71 | 21 |
| Atenolol | Atenolol | 64 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 11 |
| Mounjaro | Tirzepatide | 61 | 11 |
| Lorazepam | Lorazepam | 58 | 22 |
| Potassium Chloride | Potassium Chloride | 58 | 26 |
| Famotidine | Famotidine | 57 | 24 |
| Diazepam | Diazepam | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 15 |
| Spironolactone | Spironolactone | 56 | 17 |
| Chlorthalidone | Chlorthalidone | 55 | 13 |
| Clonazepam | Clonazepam | 54 | 12 |
| Jardiance | Empagliflozin | 53 | 14 |
| Valacyclovir | Valacyclovir Hcl | 50 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Estradiol | Estradiol | 49 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 13 |
| Tramadol Hcl | Tramadol Hcl | 48 | 20 |
| Irbesartan | Irbesartan | 46 | 14 |
| Pregabalin | Pregabalin | 46 | 14 |
| Trulicity | Dulaglutide | 46 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Finasteride | Finasteride | 43 | 17 |
| Celecoxib | Celecoxib | 41 | 13 |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 15 |
| Donepezil Hcl | Donepezil Hcl | 40 | 15 |
| Metformin Hcl Er | Metformin Hcl | 39 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | 11 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Azithromycin | Azithromycin | 25 | 22 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 14 |
| Topiramate | Topiramate | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 14 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Baclofen | Baclofen | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Easy Comfort Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.78 · 12 records | Philips North America LLC | Barostim Neo System, Cologuard Collection Kit, Diagnostic ECG Service, ENTRESTO, LEQVIO, OTEZLA, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error